Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | CDK9 | P50750 | 5/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 3/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27059762 | 1.00 | PARP1 (0.42) | PARP1CDK9CCNT1IRAK4PBK | |
| SCHEMBL27035418 | 0.95 | CDK9 (0.38) | PARP1CDK9CCNT1IRAK4PBK | |
| SCHEMBL29845331 | 0.95 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK | |
| SCHEMBL29845323 | 0.95 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK | |
| SCHEMBL24683415 | 0.95 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK | |
| Hydrochloric Acid SCHEMBL30769944 | 0.94 | CDK9 (0.38) | PARP1CDK9CCNT1IRAK4PBK | |
| Hydrochloric Acid SCHEMBL30769956 | 0.94 | CDK9 (0.38) | PARP1CDK9CCNT1IRAK4PBK | |
| Hydrochloric Acid SCHEMBL30769827 | 0.94 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK | |
| Hydrochloric Acid SCHEMBL27147682 | 0.94 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK | |
| Hydrochloric Acid SCHEMBL27035376 | 0.94 | CDK9 (0.40) | PARP1CDK9CCNT1IRAK4PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | PARP1 2161/4885CDK9 419/4885CCNT1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.